| NEWAMSTERDAM PHARMA |
| Niederlande |
| Gesundheit |
| NL00150012L7 / A3DUAC |
| KH6 (Frankfurt) / NAMS (NASDAQ) |
| FRA:KH6, ETR:KH6, KH6:GR, NASDAQ:NAMS |
| - |
| https://www.newamsterdamp.. |
|
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, especially patients whose current lipid-lowering treatments are not adequately effective or well tolerated. ..
>Volltext.. |
| 2316.67 Mio. EUR |
| 1760.06 Mio. EUR |
| 6.17 Mio. EUR |
| -211.63 Mio. EUR |
| -224.92 Mio. EUR |
| -1.89 EUR |
| 0.07 Mio. EUR |
| 368.81 Mio. EUR |
| -124.34 Mio. EUR |
| 8.7 |
| -88.52% |
| -61.52% |
| - |
| - |
| - |
| 3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.753.073 Euro. |
| NEWAMSTERDAM |
| 16.09.26 |
|